GALECTIN THERAPEUTICS INC GALT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-76.2
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$30.8M | — | — | -$127.9M |
| 2024 | — | -$47.0M | — | — | -$104.8M |
| 2023 | — | -$41.1M | — | — | -$62.0M |
| 2022 | — | -$38.8M | — | — | -$33.9M |
| 2021 | — | -$30.5M | — | — | $893,000 |
| 2020 | — | -$23.5M | — | — | $22.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer | 2026-06-23 | Option exercise | 7,557 | $1.23 |
| Jamil Khurram | Chief Medical Officer | 2026-06-23 | Sell | 7,557 | $3.14 |
| Jamil Khurram | Chief Medical Officer | 2026-05-26 | Option exercise | 568 | $1.23 |
| Jamil Khurram | Chief Medical Officer | 2026-05-26 | Sell | 568 | $3.10 |
| ELDRED KARY | director | 2026-02-06 | Buy | 300 | $2.70 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -76.2 (distress)
- Working capital / assets 0.584
- Retained earnings / assets -22.146
- EBIT / assets -1.028
- Equity / liabilities -0.878
Source: SEC EDGAR filings · CIK 0001133416 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.